top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Fragment-based approaches in drug discovery [[electronic resource] /] / edited by Wolfgang Jahnke and Daniel A. Erlanson
Fragment-based approaches in drug discovery [[electronic resource] /] / edited by Wolfgang Jahnke and Daniel A. Erlanson
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (393 p.)
Disciplina 615
615.1901
Altri autori (Persone) JahnkeWolfgang
ErlansonDaniel A
Collana Methods and principles in medicinal chemistry
Soggetto topico Drug development
Ligands (Biochemistry)
Soggetto genere / forma Electronic books.
ISBN 1-280-72281-9
9786610722815
3-527-60876-1
3-527-60860-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-based Approaches in Drug Discovery; Contents; Preface; A Personal Foreword; List of Contributors; Part I: Concept and Theory; 1 The Concept of Fragment-based Drug Discovery; 1.1 Introduction; 1.2 Starting Small: Key Features of Fragment-based Ligand Design; 1.2.1 FBS Samples Higher Chemical Diversity; 1.2.2 FBS Leads to Higher Hit Rates; 1.2.3 FBS Leads to Higher Ligand Efficiency; 1.3 Historical Development; 1.4 Scope and Overview of this Book; References; 2 Multivalency in Ligand Design; 2.1 Introduction and Overview; 2.2 Definitions of Terms
2.3 Selection of Key Experimental Studies2.3.1 Trivalency in a Structurally Simple System; 2.3.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"; 2.3.3 Oligovalency in the Design of Inhibitors to Toxins; 2.3.4 Bivalency at Well Defined Surfaces (Self-assembled Monolayers, SAMs); 2.3.5 Polyvalency at Surfaces of Viruses, Bacteria, and SAMs; 2.4 Theoretical Considerations in Multivalency; 2.4.1 Survey of Thermodynamics; 2.4.2 Additivity and Multivalency; 2.4.3 Avidity and Effective Concentration (C(eff)); 2.4.4 Cooperativity is Distinct from Multivalency
2.4.5 Conformational Entropy of the Linker between Ligands2.4.6 Enthalpy/Entropy Compensation Reduces the Benefit of Multivalency; 2.5 Representative Experimental Studies; 2.5.1 Experimental Techniques Used to Examine Multivalent Systems; 2.5.1.1 Isothermal Titration Calorimetry; 2.5.1.2 Surface Plasmon Resonance Spectroscopy; 2.5.1.3 Surface Assays Using Purified Components (Cell-free Assays); 2.5.1.4 Cell-based Surface Assays; 2.5.2 Examination of Experimental Studies in the Context of Theory; 2.5.2.1 Trivalency in Structurally Simple Systems
2.5.2.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"2.5.2.3 Oligovalency in the Design of Inhibitors of Toxins; 2.5.2.4 Bivalency in Solution and at Well Defined Surfaces (SAMs); 2.5.2.5 Polyvalency at Surfaces (Viruses, Bacteria, and SAMs); 2.6 Design Rules for Multivalent Ligands; 2.6.1 When Will Multivalency Be a Successful Strategy to Design Tight-binding Ligands?; 2.6.2 Choice of Scaffold for Multivalent Ligands; 2.6.2.1 Scaffolds for Oligovalent Ligands; 2.6.2.2 Scaffolds for Polyvalent Ligands; 2.6.3 Choice of Linker for Multivalent Ligands
2.6.3.1 Rigid Linkers Represent a Simple Approach to Optimize Affinity2.6.3.2 Flexible Linkers Represent an Alternative Approach to Rigid Linkers to Optimize Affinity; 2.6.4 Strategy for the Synthesis of Multivalent Ligands; 2.6.4.1 Polyvalent Ligands: Polymerization of Ligand Monomers; 2.6.4.2 Polyvalent Ligands: Functionalization with Ligands after Polymerization; 2.7 Extensions of Multivalency to Lead Discovery; 2.7.1 Hetero-oligovalency Is a Broadly Applicable Concept in Ligand Design; 2.7.2 Dendrimers Present Opportunities for Multivalent Presentation of Ligands
2.7.3 Bivalency in the Immune System
Record Nr. UNINA-9910144273603321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based approaches in drug discovery [[electronic resource] /] / edited by Wolfgang Jahnke and Daniel A. Erlanson
Fragment-based approaches in drug discovery [[electronic resource] /] / edited by Wolfgang Jahnke and Daniel A. Erlanson
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (393 p.)
Disciplina 615
615.1901
Altri autori (Persone) JahnkeWolfgang
ErlansonDaniel A
Collana Methods and principles in medicinal chemistry
Soggetto topico Drug development
Ligands (Biochemistry)
ISBN 1-280-72281-9
9786610722815
3-527-60876-1
3-527-60860-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-based Approaches in Drug Discovery; Contents; Preface; A Personal Foreword; List of Contributors; Part I: Concept and Theory; 1 The Concept of Fragment-based Drug Discovery; 1.1 Introduction; 1.2 Starting Small: Key Features of Fragment-based Ligand Design; 1.2.1 FBS Samples Higher Chemical Diversity; 1.2.2 FBS Leads to Higher Hit Rates; 1.2.3 FBS Leads to Higher Ligand Efficiency; 1.3 Historical Development; 1.4 Scope and Overview of this Book; References; 2 Multivalency in Ligand Design; 2.1 Introduction and Overview; 2.2 Definitions of Terms
2.3 Selection of Key Experimental Studies2.3.1 Trivalency in a Structurally Simple System; 2.3.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"; 2.3.3 Oligovalency in the Design of Inhibitors to Toxins; 2.3.4 Bivalency at Well Defined Surfaces (Self-assembled Monolayers, SAMs); 2.3.5 Polyvalency at Surfaces of Viruses, Bacteria, and SAMs; 2.4 Theoretical Considerations in Multivalency; 2.4.1 Survey of Thermodynamics; 2.4.2 Additivity and Multivalency; 2.4.3 Avidity and Effective Concentration (C(eff)); 2.4.4 Cooperativity is Distinct from Multivalency
2.4.5 Conformational Entropy of the Linker between Ligands2.4.6 Enthalpy/Entropy Compensation Reduces the Benefit of Multivalency; 2.5 Representative Experimental Studies; 2.5.1 Experimental Techniques Used to Examine Multivalent Systems; 2.5.1.1 Isothermal Titration Calorimetry; 2.5.1.2 Surface Plasmon Resonance Spectroscopy; 2.5.1.3 Surface Assays Using Purified Components (Cell-free Assays); 2.5.1.4 Cell-based Surface Assays; 2.5.2 Examination of Experimental Studies in the Context of Theory; 2.5.2.1 Trivalency in Structurally Simple Systems
2.5.2.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"2.5.2.3 Oligovalency in the Design of Inhibitors of Toxins; 2.5.2.4 Bivalency in Solution and at Well Defined Surfaces (SAMs); 2.5.2.5 Polyvalency at Surfaces (Viruses, Bacteria, and SAMs); 2.6 Design Rules for Multivalent Ligands; 2.6.1 When Will Multivalency Be a Successful Strategy to Design Tight-binding Ligands?; 2.6.2 Choice of Scaffold for Multivalent Ligands; 2.6.2.1 Scaffolds for Oligovalent Ligands; 2.6.2.2 Scaffolds for Polyvalent Ligands; 2.6.3 Choice of Linker for Multivalent Ligands
2.6.3.1 Rigid Linkers Represent a Simple Approach to Optimize Affinity2.6.3.2 Flexible Linkers Represent an Alternative Approach to Rigid Linkers to Optimize Affinity; 2.6.4 Strategy for the Synthesis of Multivalent Ligands; 2.6.4.1 Polyvalent Ligands: Polymerization of Ligand Monomers; 2.6.4.2 Polyvalent Ligands: Functionalization with Ligands after Polymerization; 2.7 Extensions of Multivalency to Lead Discovery; 2.7.1 Hetero-oligovalency Is a Broadly Applicable Concept in Ligand Design; 2.7.2 Dendrimers Present Opportunities for Multivalent Presentation of Ligands
2.7.3 Bivalency in the Immune System
Record Nr. UNINA-9910829904503321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based approaches in drug discovery / / edited by Wolfgang Jahnke and Daniel A. Erlanson
Fragment-based approaches in drug discovery / / edited by Wolfgang Jahnke and Daniel A. Erlanson
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (393 p.)
Disciplina 615
615.1901
Altri autori (Persone) JahnkeWolfgang
ErlansonDaniel A
Collana Methods and principles in medicinal chemistry
Soggetto topico Drug development
Ligands (Biochemistry)
ISBN 9786610722815
9781280722813
1280722819
9783527608768
3527608761
9783527608607
3527608605
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-based Approaches in Drug Discovery; Contents; Preface; A Personal Foreword; List of Contributors; Part I: Concept and Theory; 1 The Concept of Fragment-based Drug Discovery; 1.1 Introduction; 1.2 Starting Small: Key Features of Fragment-based Ligand Design; 1.2.1 FBS Samples Higher Chemical Diversity; 1.2.2 FBS Leads to Higher Hit Rates; 1.2.3 FBS Leads to Higher Ligand Efficiency; 1.3 Historical Development; 1.4 Scope and Overview of this Book; References; 2 Multivalency in Ligand Design; 2.1 Introduction and Overview; 2.2 Definitions of Terms
2.3 Selection of Key Experimental Studies2.3.1 Trivalency in a Structurally Simple System; 2.3.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"; 2.3.3 Oligovalency in the Design of Inhibitors to Toxins; 2.3.4 Bivalency at Well Defined Surfaces (Self-assembled Monolayers, SAMs); 2.3.5 Polyvalency at Surfaces of Viruses, Bacteria, and SAMs; 2.4 Theoretical Considerations in Multivalency; 2.4.1 Survey of Thermodynamics; 2.4.2 Additivity and Multivalency; 2.4.3 Avidity and Effective Concentration (C(eff)); 2.4.4 Cooperativity is Distinct from Multivalency
2.4.5 Conformational Entropy of the Linker between Ligands2.4.6 Enthalpy/Entropy Compensation Reduces the Benefit of Multivalency; 2.5 Representative Experimental Studies; 2.5.1 Experimental Techniques Used to Examine Multivalent Systems; 2.5.1.1 Isothermal Titration Calorimetry; 2.5.1.2 Surface Plasmon Resonance Spectroscopy; 2.5.1.3 Surface Assays Using Purified Components (Cell-free Assays); 2.5.1.4 Cell-based Surface Assays; 2.5.2 Examination of Experimental Studies in the Context of Theory; 2.5.2.1 Trivalency in Structurally Simple Systems
2.5.2.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"2.5.2.3 Oligovalency in the Design of Inhibitors of Toxins; 2.5.2.4 Bivalency in Solution and at Well Defined Surfaces (SAMs); 2.5.2.5 Polyvalency at Surfaces (Viruses, Bacteria, and SAMs); 2.6 Design Rules for Multivalent Ligands; 2.6.1 When Will Multivalency Be a Successful Strategy to Design Tight-binding Ligands?; 2.6.2 Choice of Scaffold for Multivalent Ligands; 2.6.2.1 Scaffolds for Oligovalent Ligands; 2.6.2.2 Scaffolds for Polyvalent Ligands; 2.6.3 Choice of Linker for Multivalent Ligands
2.6.3.1 Rigid Linkers Represent a Simple Approach to Optimize Affinity2.6.3.2 Flexible Linkers Represent an Alternative Approach to Rigid Linkers to Optimize Affinity; 2.6.4 Strategy for the Synthesis of Multivalent Ligands; 2.6.4.1 Polyvalent Ligands: Polymerization of Ligand Monomers; 2.6.4.2 Polyvalent Ligands: Functionalization with Ligands after Polymerization; 2.7 Extensions of Multivalency to Lead Discovery; 2.7.1 Hetero-oligovalency Is a Broadly Applicable Concept in Ligand Design; 2.7.2 Dendrimers Present Opportunities for Multivalent Presentation of Ligands
2.7.3 Bivalency in the Immune System
Record Nr. UNINA-9910876793703321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
Pubbl/distr/stampa Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016
Descrizione fisica 1 online resource (527 p.)
Disciplina 615.19
Collana Methods and Principles in Medicinal Chemistry
Soggetto topico Drug development
Drugs - Design
Ligands (Biochemistry)
Drug Discovery
LIgands
ISBN 3-527-68362-3
3-527-68360-7
3-527-68361-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction
2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery
3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References
Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References
6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery
Record Nr. UNINA-9910137167803321
Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
Pubbl/distr/stampa Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016
Descrizione fisica 1 online resource (527 p.)
Disciplina 615.19
Collana Methods and Principles in Medicinal Chemistry
Soggetto topico Drug development
Drugs - Design
Ligands (Biochemistry)
Drug Discovery
LIgands
ISBN 3-527-68362-3
3-527-68360-7
3-527-68361-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction
2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery
3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References
Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References
6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery
Record Nr. UNINA-9910676628503321
Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Pubbl/distr/stampa Chichester, U.K., : John Wiley & Sons, 2008
Descrizione fisica 1 online resource (297 p.)
Disciplina 615.19
615/.19
Altri autori (Persone) ZartlerEdward
ShapiroMichael (Michael J.)
Soggetto topico Drug development
Drugs - Design
Ligands (Biochemistry)
Soggetto genere / forma Electronic books.
ISBN 1-282-34275-4
9786612342752
0-470-72155-3
0-470-72156-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index
Record Nr. UNINA-9910144402103321
Chichester, U.K., : John Wiley & Sons, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Pubbl/distr/stampa Chichester, U.K., : John Wiley & Sons, 2008
Descrizione fisica 1 online resource (297 p.)
Disciplina 615.19
615/.19
Altri autori (Persone) ZartlerEdward
ShapiroMichael (Michael J.)
Soggetto topico Drug development
Drugs - Design
Ligands (Biochemistry)
ISBN 1-282-34275-4
9786612342752
0-470-72155-3
0-470-72156-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index
Record Nr. UNINA-9910830794403321
Chichester, U.K., : John Wiley & Sons, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Fragment-based drug discovery : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Fragment-based drug discovery : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
Pubbl/distr/stampa Chichester, U.K., : John Wiley & Sons, 2008
Descrizione fisica 1 online resource (297 p.)
Disciplina 615/.19
Altri autori (Persone) ZartlerEdward
ShapiroMichael (Michael J.)
Soggetto topico Drug development
Drugs - Design
Ligands (Biochemistry)
ISBN 9786612342752
9781282342750
1282342754
9780470721551
0470721553
9780470721568
0470721561
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index
Record Nr. UNINA-9911019963403321
Chichester, U.K., : John Wiley & Sons, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Journal of receptor, ligand and channel research
Journal of receptor, ligand and channel research
Pubbl/distr/stampa [Auckland, N.Z.], : Dove Medical Press
Disciplina 572.69605
Soggetto topico Cell receptors
Ligands (Biochemistry)
Cellular signal transduction
Receptors, Cell Surface
Ligands
Signal Transduction
Soggetto genere / forma Periodicals.
Soggetto non controllato Biophysics
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNISA-996336264003316
[Auckland, N.Z.], : Dove Medical Press
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Journal of receptor, ligand and channel research
Journal of receptor, ligand and channel research
Pubbl/distr/stampa [Auckland, N.Z.], : Dove Medical Press
Disciplina 572.69605
Soggetto topico Cell receptors
Ligands (Biochemistry)
Cellular signal transduction
Receptors, Cell Surface
Ligands
Signal Transduction
Ligands (Biochimie)
Transduction du signal cellulaire
Soggetto genere / forma Periodicals.
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNINA-9910143083903321
[Auckland, N.Z.], : Dove Medical Press
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui